HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA semi-annual agenda

This article was originally published in The Rose Sheet

Executive Summary

Oral care products that claim to reduce or prevent dental plaque and gingivitis are expected to be addressed by a notice of proposed rulemaking in May 2007, while timetables for final actions related to skin-bleaching products containing hydroquinone and the prohibition of certain cattle material in human food and cosmetics have yet to be determined, according to FDA's semi-annual agenda, which appeared in the Dec. 11 Federal Register. The agency had targeted December 2006 for a notice of proposed rulemaking on UVA/UVB sunscreens, having postponed the measure previously (1"The Rose Sheet" May 23, 2005, In Brief). An advance notice of proposed rulemaking for combination sunscreen-and-insect-repellant OTC products was also slated for release last month...

You may also be interested in...

FDA Slacking In NDI Notification Enforcement; COVID-19 'Is Not An Excuse’ – NPA

In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.

Finance Watch: Four IPOs In One Week, And Legend Is Year’s Largest So Far

Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.

FDA Says GMP Lapses In Facilities And Production Areas More Common For Cell And Gene Therapies

US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts